نتایج جستجو برای: leucovorin

تعداد نتایج: 2615  

Journal: :Japanese journal of clinical oncology 2010
Hidetomo Ajima Hiroyasu Ogata Ken-ichi Fujita Keisuke Miwa Yu Sunakawa Keiko Mizuno Hiroo Ishida Keishi Yamashita Hirofumi Nakayama Kaori Kawara Harumi Takahashi Yasutsuna Sasaki

OBJECTIVE Recently, significant progress in treatment of metastatic colorectal cancer has been achieved. Either FOLFIRI (fluorouracil, leucovorin and irinotecan) or modified FOLFOX6 (fluorouracil, leucovorin and oxaliplatin, oxaliplatin dose 85 mg/m(2)) is selected as first-line therapy in clinical practice in Japan. However, economic burden of colorectal cancer is considerable. METHODS Analy...

Journal: :Oncology 2000
C Bokemeyer J T Hartmann F Mayer I Böhlke L Kanz J Von Pawel G Derigs M Schröder

The palliation of symptoms and improvement of quality of life are important aspects of therapy in patients with incurable metastatic cancer. This article describes the preliminary results of a phase I study of uracil and tegafur, an orally available fluorouracil (5-FU) derivative combined with oral leucovorin plus weekly intravenous paclitaxel. While the daily oral dose of UFT is fixed at 300 m...

2016
Zhi-Qiang Wang Dong-Sheng Zhang Nong Xu De-Yun Luo Yan-Hong Deng Feng-Hua Wang Hui-Yan Luo Miao-Zhen Qiu Yu-Hong Li Rui-Hua Xu

BACKGROUND Fluoropyrimidine and oxaliplatin are widely used for patients with colorectal cancer. This phase II study was conducted to evaluate the efficacy and safety of the combination of S-1, oxaliplatin, and leucovorin (SOL) in the treatment of Chinese patients with metastatic colorectal cancer (mCRC). METHODS Eligible patients with untreated mCRC from four hospitals in China received intr...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2003
S H Park D Y Kim J S Heo D H Lim C K Park K W Lee S H Choi T S Sohn S Kim J H Noh Y I Kim J O Park K Kim W S Kim C W Jung Y H Im M H Lee K Park C H Park W K Kang

BACKGROUND We report the results of postoperative chemoradiotherapy after curative resection in gastric cancer patients. PATIENTS AND METHODS Patients with gastric cancer staged IB to IV(M0) were treated with chemoradiotherapy after curative resection with extensive (D2) lymph node dissection. Nodal metastases were observed in 261 (90%) patients. The chemotherapy consisted of fluorouracil 400...

2013
Kristen K. Ciombor Emily Chan

Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor (PlGF) agent, has recently been approved by the U.S. Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously received an oxaliplatin-containing chemotherapy regimen. In the phase III...

2002
CURTIS J. OLESCHUK ROGER G. DEELEY SUSAN P. C. COLE Roger G. Deeley

Oleschuk, Curtis J., Roger G. Deeley, and Susan P. C. Cole. Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol 284: G280–G289, 2003. First published October 9, 2002; 10.1152/ajpgi.00331.2002.—Multidrug resistance protein 3 (MRP3) is an ATP-dependent transporter of 17 -estradiol 17 (D-glucuronide) (E217 G)...

Journal: :Anticancer research 2007
Chia-Chi Lin Ann-Lii Cheng Chih-Hung Hsu Yen-Shen Lu Chiun Hsu Kun-Huei Yeh Chen-Yao Wu Chiun-Sheng Huang Chih-Hsin Yang

BACKGROUND Weekly paclitaxel and infusional high-dose 5-fluorouracil/leucovorin (HDFL) are both effective regimens for metastatic breast cancer (MBC) patients. PATIENTS AND METHODS A study was designed using weekly paclitaxel 90 mg/m(2) 1-hour infusion followed by 2,000 mg/m(2) 5-fluorouracil plus 300 mg/m(2) leucovorin 24-hour infusion on days 1, 8 and 15, repeated every 28 days, in patients...

2012
Seon Ae Roh Eun Young Choi Dong Hyung Cho Yong Sik Yoon Tae Won Kim Yong Sung Kim Jin Cheon Kim

PURPOSE Identification of subgroups of patients who differ in their response to treatment could help to establish which of the best available chemotherapeutic options are best, based on biological activity. In metastatic colorectal cancer (CRC), novel molecular-targeted agents that act on pathways that regulate cell growth, the cell cycle, apoptosis, angiogenesis, and invasion are being develop...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2003
G F Fleming R L Schilsky L P Schumm A Meyerson A M Hong N J Vogelzang M J Ratain

BACKGROUND Patients with hepatic or renal dysfunction are often treated with 5-fluorouracil (5-FU), but there are few data to confirm the safety of this practice. PATIENTS AND METHODS Patients with solid tumors were eligible if they were able to fit into one of three organ dysfunction cohorts: I, creatinine >1.5 but < or =3.0 mg/dl and normal bilirubin; II, bilirubin >1.5 but <5.0 mg/dl with ...

Journal: :Tumori 2007
Nicla La Verde Marina Garassino Claudia Bareggi Paola Sburlati Karen Borgonovo Mariastella Dimaiuta Cristina Mantica Silvia Perrone Valter Torri Gabriella Farina

AIMS AND BACKGROUND The purpose of the study was to evaluate the outcome of metastatic colorectal cancer patients treated, as first line, with 5-fluorouracil bolus/leucovorin + oxaliplatin, in terms of response, progression-free and overall survival. MATERIALS AND METHODS A retrospective cohort of consecutive metastatic colorectal cancer patients, treated from 2003 to 2006, was identified and...

20042005200620072008200920102011201220132014201520162017201820192020202120222023050100150200

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید